In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

• Published in: The New England journal of medicine Vol. 387; no. 22; pp. 2094 - 2097
• Main Authors: Takashita, Emi, Yamayoshi, Seiya, Halfmann, Peter, Wilson, Nancy, Ries, Hunter, Richardson, Alex, Bobholz, Max, Vuyk, William, Maddox, Robert, Baker, David A., Friedrich, Thomas C., O’Connor, David H., Uraki, Ryuta, Ito, Mutsumi, Sakai-Tagawa, Yuko, Adachi, Eisuke, Saito, Makoto, Koga, Michiko, Tsutsumi, Takeya, Iwatsuki-Horimoto, Kiyoko, Kiso, Maki, Yotsuyanagi, Hiroshi, Watanabe, Shinji, Hasegawa, Hideki, Imai, Masaki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 01.12.2022
• Subjects: Antibodies, Viral - immunology; Antiviral agents; Antiviral Agents - immunology; Antiviral Agents - pharmacology; Coronavirus; Coronaviruses; COVID-19 - genetics; COVID-19 - immunology; COVID-19 - virology; COVID-19 vaccines; Disease transmission; Drug dosages; FDA approval; Humans; In Vitro Techniques; Infectious Disease; Infectious diseases; Influenza; Medical research; Monoclonal antibodies; Mutation; Pathogenesis; R&D; Research & development; RNA polymerase; SARS-CoV-2 - drug effects; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Vaccine Efficacy; Viral Infections; United States > US; Japan

Efficacy of Antiviral Agents against Omicron BA.4.6Researchers report that antiviral agents remdesivir, molnupiravir, and nirmatrelvir and monoclonal antibodies bebtelovimab and imdevimab retain effectiveness against the BA.4.6 subvariant in vitro.